

## **Profile Boehringer Ingelheim**

### **1. Company**

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates and more than 41,300 employees. It was founded in 1885 and until today is a family-owned company.

### **2. Core Competences**

Since its foundation, Boehringer Ingelheim has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. We have four major R&D Centers in Europe and North America, which focus on seven major therapeutic areas: Respiratory diseases, Virology, Oncology, CardioMetabolic diseases, Central nervous system, Immunology and Inflammation.

### **3. Cooperations offered and requested**

Boehringer Ingelheim has alliances with pharmaceutical and biotech companies around the globe. With a track record in R&D, registration and marketing, Boehringer Ingelheim is seeking partnerships, alliances and licensing opportunities with a primary focus in its therapeutic areas respiratory, virology, cardiometabolic diseases, CNS, oncology, urology, immunology and inflammation, and enabling technologies. In addition to our interest in in-licensing, we also offer our biopharmaceutical development and GMP manufacturing services to interested partners.

**Prof. Dr. Gerd Schnorrenberg**

**Wissenschaftlicher Werdegang**

- 1971 - 1978 Chemiestudium an der Rheinischen Friedrich-Wilhelms-Universität Bonn
- 1978 Diplom
- 1978 - 1981 Promotionsarbeit im Arbeitskreis Prof. W. Steglich  
Thema der Promotionsarbeit "4,6-Diphenyl-thieno [3,4-d] [1,3] dioxol-2-on-5,5-dioxid als Aktivierungsmittel in der Peptidsynthese"
- 1981 Laborleiter der Abteilung Pharmachemie, Boehringer Ingelheim KG, Ingelheim
- 1982 Leiter Mer-Preis der Rheinischen Friedrich-Wilhelms-Universität Bonn für die Promotionsarbeit
- 1991 Studienaufenthalt im Arbeitskreis von M. Goodman, University of California, San Diego und im Arbeitskreis von D. Kemp, Massachusetts Institute of Technology, Boston
- 1992 Lehrauftrag für Medizinische Chemie an der Johannes Gutenberg-Universität, Mainz
- 1994 Leiter der Abteilung Chemische Forschung, Boehringer Ingelheim KG, Ingelheim
- 1997 Leiter der Abteilung Chemische Forschung, Dr. Karl Thomae GmbH, Biberach
- 1998 Honorarprofessur des Bundeslandes Rheinland-Pfalz
- 1999 Leiter der Abteilung Chemische Forschung, Boehringer Ingelheim Pharma KG, Biberach und Ingelheim, seit 2001 Biberach
- seit 2008 Geschäftsführer des Geschäftsführungsbereichs Forschung, Boehringer Ingelheim Pharma GmbH & Co. KG